Aripiprazole (Apicord (20 mg)) is an atypical antipsychotic and antidepressant, prescribed for schizophrenia and depression. It regulates abnormal conditions like disturbed or unusual thinking, loss ...

Aripiprazole is a generic drug prescribed for certain conditions, including schizophrenia, in adults and some children. The medication is available as the brand-name drugs Abilify, Abilify Asimtufii, ...

Abilify is available in several different brand-name versions: Abilify comes as a tablet that you swallow. Abilify MyCite comes as a tablet with a sensor that you swallow.* Abilify Maintena comes as ...

Abilify 20 mg tablets — single dose cost over the internet. Aripiprazole is an atypical antipsychotic orally indicated for treatment of schizophrenia, bipolar I, major depressive disorder, ...

Inpatient Starting dose 15 mg/day From day 2: dose may be increased up to 30 mg/day if necessary The dose may be reduced to 10 mg/day if tolerability problems arise (also see table II for management ...

If approved, aripiprazole 2-month ready-to-use (RTU), long-acting injectable (LAI) would be the first 2-month, LAI antipsychotic indicated for both treatment of schizophrenia and the maintenance ...

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1 Windsor, United Kingdom/Valby, Denmark, 27 March 2024 – Otsuka Pharmaceutical ...

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...

November 24, 2009 — The US Food and Drug Administration (FDA) has approved an expanded indication for the oral formulation of aripiprazole (Abilify tablets, orally disintegrating tablets, and oral ...

Otsuka America Pharmaceutical, Inc. (Otsuka) and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ABILIFY ASIMTUFII ® (aripiprazole) ...